Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01482299
Other study ID # AMC1104
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date November 2011
Est. completion date January 2014

Study information

Verified date January 2020
Source Asan Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a phase II study to evaluate RAD001 (Everolimus) in terms of 4-month progression-free survival rate (primary end-point) and response rate, toxicity, overall survival and biomarker assessment (secondary end-points) in patients with metastatic or recurrent gastric cancer with pS6 Ser 240/4 expression.

Eligibility criteria include pathologically proven non-resectable adenocarcinoma of stomach with measurable disease who failed previous first-line palliative chemotherapy including fluoropyrimidine and platinum with high expression of pS6 Ser 240/4.

Oral RAD001 (everolimus) 10mg daily will be administered and the dose will be adjusted according to the observed clinical toxicities. Treatment will be continued until disease progression or patient's intolerability to the study drug.

A study requires 40 assessable subjects to decide whether the proportion of patients who are free from progression at 4 months (16 weeks), P, is less than or equal to 0.1 or greater than or equal to 0.25 with a target error rate of 0.05 and β of 0.2. If the number of responses is 7 or less, the hypothesis that P >= 0.250 is rejected with a target error rate of 0.200 and an actual error rate of 0.182. If the investigators assume that drop-out rate is 10%, total accrual patient will be 45.


Description:

Methodology: Prospective, non blinded, open label, single center phase II study

Criteria for evaluation: Assessment of response will be assessed radiologically according to RECIST criteria after completion of the two cycles. Evaluation will be by physical examination, chest X-ray, abdomen-pelvis CT scan Safety criteria: Physical examination, vital signs, performance status, CBC, serum chemistry, NCI CTC V.3.0


Recruitment information / eligibility

Status Completed
Enrollment 45
Est. completion date January 2014
Est. primary completion date January 2014
Accepts healthy volunteers No
Gender All
Age group 20 Years to 75 Years
Eligibility Inclusion Criteria:

- histologically or cytologically documented stomach adenocarcinoma including adenocarcinoma of the esophagogastric junction

- non-resectable disease by metastasis or recurrent disease after curative surgical resection (See Appendix A) with uni-dimensionally measurable disease

- failure of 1st line chemotherapy including fluoropyrimidine (capecitabine, S1, or 5-FU,) and platinum (cisplatin or oxaliplatin) in palliative setting; progression during or within 6 months after chemotherapy

- High expression of pS6 Ser 240/4 (proportion of pS6 Ser 240/4 positive cancer cells by immunohistochemistry > 10%)

- Age 20 to 75 years old

- Estimated life expectancy of more than 3 months

- ECOG performance status of 2 or lower

- Adequate bone marrow function

- Adequate kidney function

- Adequate liver function

- Fasting serum cholesterol = 300 mg/dL AND fasting triglyceride = 2.5 X ULN

- No prior radiation therapy to more than 25% of BM

- psychological, familial, sociological or geographical conditions which do not permit medical follow-up and compliance with this study

- Women of childbearing potential must have a negative pregnancy test on admission

- Written informed consent

Exclusion Criteria:

- Other tumor type than adenocarcinoma

- CNS metastases or prior radiation for CNS metastases

- Gastric outlet obstruction or intestinal obstruction

- Evidence of active gastrointestinal bleeding

- Bone lesions as the sole evaluable disease

- Past or concurrent history of neoplasm other than stomach cancer

- Pregnant or lactating women, women of childbearing potential not employing adequate contraception

- Other serious illness or medical conditions

- Concomitant or with a 4-week period administration of any other experimental drug under investigation

- Concomitant chemotherapy, hormonal therapy, or immunotherapy

- Any preexisting medical condition of sufficient severity to prevent full compliance with the study

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
RAD001
RAD001 (everolimus) 10 mg daily, orally without interruption. 1 cycle is equal to 4-week treatment. Treatment will be continued unless disease progression or intolerability.

Locations

Country Name City State
Korea, Republic of Asan Medical Center Songpa-gu Seoul

Sponsors (1)

Lead Sponsor Collaborator
Asan Medical Center

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary 4-month progression-free survival Progression-free survival is defined as the time from the first treatment to the onset of progressive disease per RECIST criteria or to the date of death whichever comes first. For patients who do not experience progressive disease or death, the progression-free survival duration will be right censored on the last disease assessment date. up to 3years
Secondary Response rate evaluated with abdominal and pelvic dynamic CT scan every 8 weeks, using RECIST version 1.0 Up to 1year
Secondary Number of participants with adverse events Adverse events will be graded according to Common Terminology Criteria for Adverse events version 4.0 Monitoring of adverse events will be contineud for at least 28days following the last dose of study treatment
Secondary Overall survival Overall survival duration is calculated as time from the first treatment to the date of death. For patients who are still alive at the cut-off date for statistical reporting, the overall survival duration will be right censored on the last known alive date. Up to 3years
Secondary Biomarker assessment Tumor tissues obtained by tumor tissues can be used for immunohistochemistry(IHC) of pS6 Ser 240/4. In patients who did not receive gastrectomy tumor biopsies will be obtained at screening(before everolimus treatment) and after two cycles of treatment. Scoring of all IHC results is based on the percentage of positive cells. The percentage of positive cells is scored as: 0 (0%); 1 (=10%); 2 (11-33%); 3 (34-66%); 4 (=67%). 24months
See also
  Status Clinical Trial Phase
Completed NCT03313700 - Clinical Outcomes of Robotic Versus Laparoscopic Distal Gastrectomy for Gastric Cancer N/A
Recruiting NCT05645198 - The Effect of Carboxymetyl Starch (Oozfix) on Preventing Postoperative Complication After Gastrectomy Phase 4
Completed NCT03549494 - Evaluation of Ocoxin®-Viusid® in Advanced Stomach Cancer and Gastric Esophagogastric Junction Phase 2
Completed NCT00144378 - Irinotecan Versus Only Best Supportive Care for Gastric Cancer Phase 3
Completed NCT00935779 - Ultra Structure Of Peritoneum At Electronic Microscopy In Control Subjects And Patients With Gastric Cancer N/A
Completed NCT00290966 - Randomized Multicenter Study Comparing Docetaxel Plus Cisplatin and 5-FU to Cisplatin Plus 5-FU in Advanced Gastric Cancer Phase 2/Phase 3
Recruiting NCT03348150 - Gastrectomy + Cytoreductive Surgery + HIPEC for Gastric Cancer With Peritoneal Dissemination. Phase 3
Not yet recruiting NCT06085677 - The Gastric HormonE BioMarkers of Preneoplastic Lesions Study
Recruiting NCT02969122 - Treatment Strategy for Stage IV Gastric Cancer With Positive Peritoneal Cytology as the Only Non-curable Factor N/A
Active, not recruiting NCT03760822 - Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal Junction Cancer Patients Phase 2
Recruiting NCT00509964 - Second-Line Irinotecan vs. ILF for AGC Phase 2
Completed NCT04889859 - Impact of Biliopancreatic Limb Length on Diabetes Following Distal Gastrectomy N/A
Completed NCT03071237 - The Origin of Infrapyloric Artery
Recruiting NCT05184803 - A Phase 2 Study of Neoadjuvant Docetaxel, Oxaliplatin, S-1 in Patients With Unresectable Locally Advanced or Distant Metastasis Limited to Lymph Node Gastric Cancer Phase 2
Completed NCT05714878 - Multimodal Prehabilitation for Resectable Gastric Cancer N/A
Completed NCT00142038 - Docetaxel and Capecitabine in Advanced Gastric Cancer Phase 2
Not yet recruiting NCT04056260 - ICG-NIR Guided Lymph Node Dissection in Gastric Cancer N/A
Recruiting NCT03065257 - Endoscopic Resection Multicenter Registry N/A
Recruiting NCT04744649 - Neoadjuvant Immunotherapy and Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer Trial Phase 2
Recruiting NCT05640609 - Capeox Regimen Combined With Sintilimab and Bevacizumab for Gastric Cancer Phase 1/Phase 2